Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of GSK2696277 gene therapy in transfusion-dependent beta-thalassemia (TIGET-BTHAL follow-on)
2017-001366-14Phase 2Terminated
- Sponsor
- GSK
- Start
- Feb 2020
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GLOBE in beta thalassemia, sponsored by GSK. Primary endpoint: Absence of lentiviral gene-therapy specific adverse events. Started Feb 2020; status: terminated.
02
Drugs
GLOBE
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on 2017-001366-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001366-14.